5 Key Takeaways
-
1
Alcon plans to acquire Staar Surgical for approximately $1.5 billion, including the EVO family of lenses for vision correction.
-
2
Alcon's Tryptyr, a new treatment for dry eye disease, is now available for prescription following FDA approval in May.
-
3
Lenz Therapeutics received FDA approval for Vizz, an eye drop for presbyopia that improves near vision without myopic shift.
-
4
EyePoint Pharmaceuticals completed enrollment for its phase 3 LUCIA trial, evaluating a potential treatment for neovascular age-related macular degeneration.
-
5
Cloudbreak Pharma reported positive phase 2 trial results for CBT-004, showing significant improvements in patients with vascularized pinguecula.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.